Adult Dosing

Production of miosis

• Up to 0.5 mL intraocular injection x1 into the anterior chamber before or after securing sutures

Post operative prevention of intraocular pressure

• Up to 0.5 mL intraocular injection x1 into the anterior chamber before or after securing sutures

Pediatric Dosing

• Safety and effectiveness in pediatrics have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• For obtaining miosis during surgery
• For reduction of the intensity of intraocular pressure elevation in the first 24 hrs after cataract surgery

• Hypersensitivity to any of the ingredients of the product
• Acute iritis
• Anterior or acute uveitis
• Acute anterior chamber inflammation

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Only for single-dose intraocular use
• Discard any unused portion

Cautions: Use cautiously in

• Acute cardiac failure
• Bronchial asthma
• Peptic ulcer
• Hyperthyroidism
• G.I. spasm
• Urinary tract obstruction
• Parkinson's disease

Pregnancy Category:C

Breastfeeding: Literatures are unavailable on the use of carbachol ophthalmic drops during breastfeeding. As it posses short half-life, it is unlikely to reach the bloodstream of the infant and induce any adverse effects in breastfed infants. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 2 March 2011). Manufacturer advises caution.

• EENT: Corneal opacification, bullous keratopathy, retinal detachment, iritis
• CNS: Headache
• DERM: Flushing, diaphoresis
• GI: Epigastric discomfort, abdominal cramps, bladder tightness

• Parasympathomimetic; precise mechanism of action is unknown; stimulates both muscarinic and nicotinic receptors, produces constriction of the iris and ciliary body and results in reduction of intraocular pressure
• Metabolism: Unknown; CYP450: Unknown
• Excretion: Unknown
• Half-life: Unknown

US Trade Name(s)

• Miostat

US Availability

Miostat

• INJ: 0.01% (2 mL vial)

Canadian Trade Name(s)

• Miostat

Canadian Availability

Miostat

• INJ: 0.01%

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• Miostat

Australian Availability

Miostat

• INJ: 0.01%

[Outline]

Ophthalmic

Ophthalmic Glaucoma Agents